SomaLogic’s 7K SomaScan® Platform receives high marks in independent technical assessment by researchers at the National Institutes of Health
The National Institutes of Health recently conducted a technical assessment of the 7K SomaScan® Platform, revealing its strengths in proteome coverage, sensitivity, and low variability. The study evaluated 2,050 plasma samples across 102 subjects, confirming the platform's capability in biomarker discovery and diagnostic applications. SomaLogic's Chief Medical Officer emphasized the platform's power in measuring protein concentrations, stating it significantly outperformed traditional assays. This independent validation supports SomaLogic's ongoing improvement and growth in proteomic research.
- SomaScan Platform demonstrates high sensitivity with only seven proteins below the detection limit.
- Independent validation enhances credibility, showcasing strengths over traditional proteomic approaches.
- Opportunity for biomarker discovery and clinical applications.
- None.
BOULDER, Colo., Oct. 27, 2022 (GLOBE NEWSWIRE) -- In a recent paper published earlier this month in Nature Scientific Reports, researchers at the National Institutes of Health conducted what may be the largest technical assessment to date of the 7K SomaScan® Platform to measure its performance and to support the platform’s growing community of users. The researchers found the platform’s extensive proteome coverage, sensitivity and consistently low variability to be particular strengths, and describe these strengths as key advantages over other proteomic approaches.
As part of the study, the NIH researchers performed proteomic profiling on a total of 2,050 plasma samples across 22 plates from 102 human subjects. The research team found the SomaScan Platform to have high sensitivity. During the study researchers found that only seven of the 7,000 proteins on the SomaScan Platform were signaling below their estimated limit of detection.
The NIH research team emphasized the opportunities offered by the SomaScan Platform, highlighting the growth of the platform over the years to its current coverage of 7,000 proteins, as well as the consistently low variability it delivers. The authors concluded that the platform could be used in several different ways including biomarker discovery and learning about biological processes in response to disease or treatment; as a diagnostic tool for determining which patients need the most immediate treatment; and uncovering the complex relationship between the genome and proteome.
“The SomaScan Platform is a powerful tool for biomarker discovery across a range of diseases and conditions,” said SomaLogic Chief Medical Officer Steve Williams. “Without missing values, relative concentrations measured in experimental samples in this study turned out to be significantly higher than background for almost the entire menu of our SOMAmers – an indication of remarkable sensitivity. We agree with the manuscript’s claim that this is a major departure from all antibody-based and most other proteomic assays.”
Researchers at the NIH have used the SomaScan Platform since the time the assay covered 1,100 proteins. In 2015 and 2017, teams at the NIH assessed the technical features of the 1.1k and 1.3k SomaScan Platform and published their findings. The NIH team conducted the technical assessment of the 7k platform to serve as a technical reference for future studies.
“We are constantly growing and improving our platform and these studies are important from the standpoint of validating its accuracy and giving us areas of focus for refining it,” says SomaLogic Chief Technology Officer Jason Cleveland. “This independent technical assessment gives us confidence in the direction of the SomaScan Platform to be a driving force for basic, translational and clinical research communities.”
SomaLogic’s proprietary SomaScan Platform was designed to be a universal platform that can be applied across research and discovery, translational research and biopharmaceutical development, and clinical applications. SomaLogic can run approximately 7,000 protein measurements on a single 55 microliter plasma or serum sample. The company has run more than 550,000 samples to date.
About SomaLogic
SomaLogic (Nasdaq: SLGC) seeks to deliver precise, meaningful and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners and users, is derived from SomaLogic’s personalized measurement of important changes in an individual’s proteins over time. For more information, visit www.somalogic.com and follow @somalogic on Twitter.
Forward Looking Statements Disclaimer
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements, other than statements of historical fact included in this press release, regarding our strategy, future operations, financial position, estimated revenues, projections, prospects, plans and objectives of management are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “forecast,” “guidance,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “continue,” “will likely result,” “possible,” “potential,” “predict,” “pursue,” “target” and similar expressions, although not all forward-looking statements contain such identifying words. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements do not guarantee future performance and involve known and unknown risks, uncertainties and other factors. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including factors which are beyond SomaLogic’s control. You should carefully consider these risks and uncertainties, including, but not limited to, those factors described under Part I, Item 1A – “Risk Factors” in our Annual Report on Form 10-K and other filings we make with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SomaLogic assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The Company will not and does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Media Contact
Emilia Costales
720-798-5054
ecostales@somalogic.com
Marissa Bych
Gilmartin Group LLC
Marissa@gilmartinir.com
FAQ
What did the NIH study reveal about the 7K SomaScan Platform (SLGC)?
How many samples were analyzed in the NIH assessment of the SomaScan Platform (SLGC)?
What are the potential applications of the SomaScan Platform (SLGC)?
Who emphasized the power of the SomaScan Platform (SLGC) for biomarker discovery?
What is the current protein coverage of the SomaScan Platform (SLGC)?
